Paperpal Prime Logo

Clinical Immunology Communications : Impact Factor & More

eISSN: 2772-6134
JournalOpen Access
Recommended pre-submission checks
Powered by Paperpal by Editage

Clinical Immunology Communications Journal Specifications

Indexed in the following public directories

  • Scopus Scopus
  • DOAJ DOAJ
Overview
Publisher Elsevier
Language English
Article Processing ChargesUSD 1750
Publication Time10
Editorial Review ProcessBlind peer review
General Details
LanguageEnglish
Website URLVisit website
Publication Details
PlagiarismVisit website
Publication Time 10
Waiver PolicyVisit website
Editorial Review Detail
Editorial TeamVisit website
Review ProcessBlind peer review
Review UrlVisit website
Information for authors
Author instructionsVisit website
Copyright DetailsVisit website
License typeCC BY, CC BY-NC-ND
OA statementVisit website
View less

Planning to publish in Clinical Immunology Communications ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Clinical Immunology Communications

Secondary immunodeficiency after B-cell depletion: Mechanisms, clinical manifestations, monitoring, and management
  • 1 Dec 2026
  • Clinical Immunology Communications
Anti-DFS70 antibodies are associated with acute Epstein-Barr virus infection: a pilot study
  • 1 Dec 2026
  • Clinical Immunology Communications
Recurrent homozygous FASLG pathogenic variant in an unrelated consanguineous Moroccan family with ALPS: a possible North African founder allele
  • 1 Dec 2026
  • Clinical Immunology Communications
HIV-1/HTLV-1 coinfection drives coordinated adaptive and innate immune dysregulation associated with increased risk of disease progression: a pilot exploratory study
  • 1 Dec 2026
  • Clinical Immunology Communications
Towards broadly protective hantavirus vaccine: Immunological barriers, structural vaccinology and one health perspectives
  • 1 Dec 2026
  • Clinical Immunology Communications
Rapid suppression of unresolving disseminated coccidioidomycosis infection with combined IL-15 super-agonist (N-803) and invariant natural killer T cell therapy
  • 1 Dec 2026
  • Clinical Immunology Communications
Secondary immunodeficiency after B-cell depletion: Mechanisms, clinical manifestations, monitoring, and management
  • 1 Dec 2026
  • Clinical Immunology Communications
Anti-DFS70 antibodies are associated with acute Epstein-Barr virus infection: a pilot study
  • 1 Dec 2026
  • Clinical Immunology Communications
Recurrent homozygous FASLG pathogenic variant in an unrelated consanguineous Moroccan family with ALPS: a possible North African founder allele
  • 1 Dec 2026
  • Clinical Immunology Communications
HIV-1/HTLV-1 coinfection drives coordinated adaptive and innate immune dysregulation associated with increased risk of disease progression: a pilot exploratory study
  • 1 Dec 2026
  • Clinical Immunology Communications
Towards broadly protective hantavirus vaccine: Immunological barriers, structural vaccinology and one health perspectives
  • 1 Dec 2026
  • Clinical Immunology Communications
Rapid suppression of unresolving disseminated coccidioidomycosis infection with combined IL-15 super-agonist (N-803) and invariant natural killer T cell therapy
  • 1 Dec 2026
  • Clinical Immunology Communications

FAQs on Clinical Immunology Communications